Trials / Completed
CompletedNCT04534439
Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy
A Randomized, Placebo-controlled, Double-blinded, Multi-centre, Phase 2 Study to Assess Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 140 (actual)
- Sponsor
- Aptabio Therapeutics, Inc. · Individual
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a proof of concept (PoC) trial to evaluate the safety, tolerability and renal effect of APX-115 in subjects with Type 2 diabetes and nephropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APX-115 | oral administration of APX-115 400mg capsule once daily for 12 weeks |
| DRUG | Placebo | oral administration of APX-115-matching placebo 400mg capsule once daily for 12 weeks |
Timeline
- Start date
- 2020-08-24
- Primary completion
- 2021-07-26
- Completion
- 2021-08-23
- First posted
- 2020-09-01
- Last updated
- 2021-08-25
Locations
16 sites across 4 countries: Bulgaria, Czechia, Hungary, Serbia
Source: ClinicalTrials.gov record NCT04534439. Inclusion in this directory is not an endorsement.